One form of treatment for MS patients used to date, which has been associated with simultaneous upregulation of IL-6 and IL-10, is therapy with glatiramer acetate (GA), a myelin basic protein (MBP) analogue approved by the Food Drug Association (FDA) [60,61]. This evidence concerns the gene IL10 and myeloid sarcoma.